Policy Update: X-Waiver

The Department of Health and Human Services (HHS) has halted plans to expand access to buprenorphine and eliminate the X-waiver.

Policy Update: X-Waiver

Download Letter Updated: January 29, 2021 The Issue: Buprenorphine, a partial opioid medication, is an effective addiction treatment. It is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning that the drug is highly regulated. Under the Drug Addiction Treatment Act, clinicians can only prescribe buprenorphine, with very limited exceptions, if […]

SHM Sends Letter to the Federation of State Medical Boards Regarding Mental Health Disclosures and State Licensure

SHM urges the FSMB to encourage its member boards to revisit mental health disclosure policies for state licensure and prioritize advocacy efforts with state legislatures. Eliminating mental health disclosure requirements or contextualizing these disclosures as they pertain to actual impairments will help foster a healthier and more supportive profession, particularly in these extraordinarily trying times.